Drug profile · INN
palbociclib
IBRANCE
- US status
- approved
- Patents linked
- 1
- News articles
- 0
Quick answer
palbociclib (IBRANCE) is an FDA-listed pharmaceutical active ingredient. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN palbociclib
Brand IBRANCE
Route ORAL
Formulation CAPSULE
ATC code L01EF01
Originator Pfizer Australia Pty Ltd
Related patents
Search patents →Frequently asked questions
What is palbociclib?
palbociclib (IBRANCE) is an FDA-listed pharmaceutical active ingredient. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for palbociclib?
IBRANCE is a marketed brand name for palbociclib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of palbociclib?
palbociclib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.